VYNE Therapeutics (Ticker: VYNE) CFO reports tax-share withholding event

Rhea-AI Filing Summary

VYNE Therapeutics Inc. reports that Chief Financial Officer Tyler Zeronda had 22,516 shares of common stock withheld on 2026-07-23 to satisfy tax withholding requirements arising from the vesting of restricted stock units, at $0.8976 per share. After this tax-withholding disposition, Zeronda directly holds 74,918 shares of VYNE common stock.

Insider Trade Summary

Net Seller: 22,516 shares

Net Sell 1 txn

Insider Zeronda Tyler

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	22,516	$0.8976	$20K

Holdings After Transaction: Common Stock — 74,918 shares (Direct)

Footnotes (1)

1. F1. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Key Figures

Shares withheld for taxes: 22,516 shares Per-share value for withholding: $0.8976 per share Shares held after transaction: 74,918 shares

3 metrics

Shares withheld for taxes 22,516 shares Shares of common stock withheld on 2026-07-23 to satisfy tax withholding for RSU vesting

Per-share value for withholding $0.8976 per share Value per share applied to the 22,516 withheld shares

Shares held after transaction 74,918 shares Direct holdings of CFO Tyler Zeronda following the 2026-07-23 tax-withholding disposition

Key Terms

restricted stock units, tax withholding requirements, withheld by the Issuer

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding requirements financial

"withheld by the Issuer to satisfy tax withholding requirements"

withheld by the Issuer financial

"Represents shares that have been withheld by the Issuer"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/24/2026 - 05:00 PM Accepted by SEC EDGAR 07/24/2026 - 05:00 PM Learn about SEC filing dates

FAQ

What insider transaction did VYNE (VYNE) report for its CFO?

VYNE reported that CFO Tyler Zeronda had 22,516 shares of common stock withheld on 2026-07-23 to cover tax obligations from vesting restricted stock units, rather than through an open-market sale.

How many VYNE (VYNE) shares does the CFO hold after the tax withholding?

Following the tax-withholding disposition, CFO Tyler Zeronda directly holds 74,918 shares of VYNE Therapeutics common stock, as reported in the Form 4 insider trading report filed for the 2026-07-23 transaction.

What was the per-share value used for VYNE (VYNE) CFO’s tax withholding?

The shares withheld to satisfy the CFO’s tax obligations were valued at $0.8976 per share. This per-share value applies to the 22,516 shares withheld in connection with the vesting of restricted stock units.

Was the VYNE (VYNE) CFO’s Form 4 transaction a sale on the open market?

The transaction was reported as shares withheld by the issuer to satisfy tax withholding requirements for vesting restricted stock units, not as a discretionary open-market purchase or sale of VYNE common stock by the CFO.

What security was involved in the VYNE (VYNE) CFO’s reported transaction?

The transaction involved Common Stock of VYNE Therapeutics Inc. Shares were withheld to cover taxes due on the vesting of restricted stock units, reducing reported holdings but not representing a market sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zeronda Tyler

(Last) (First) (Middle)

C/O VYNE THERAPEUTICS INC.

P.O. BOX 125

(Street)

STEWARTSVILLE NEW JERSEY 08886

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VYNE Therapeutics Inc. [ VYNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		F(1)		22,516	D	$0.8976	74,918	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

	/s/ Mutya Harsch, Attorney-in-Fact	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)